Also trades as: 4521.T (JPX) · $vol 3M
KKPCF OTC
Kaken Pharmaceutical Co., Ltd.
1W: +0.0%
1M: -2.4%
3M: -2.4%
YTD: +7.4%
1Y: -7.5%
3Y: -6.0%
5Y: -26.6%
$26.00
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Balance Sheet Trends
Total Assets
$179.3B
-5.8% ▼
5Y CAGR: +1.9%
Total Liabilities
$30.8B
-18.5% ▼
5Y CAGR: +2.6%
Shareholders Equity
$148.5B
-2.7% ▼
5Y CAGR: +1.7%
Cash & Investments
$51.0B
-27.2% ▼
5Y CAGR: -8.0%
Total Debt
$3.9B
+0.6% ▲
5Y CAGR: +0.1%
Net Debt
-$41.1B
+18.2% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $61.0B | $59.6B | $50.6B | $54.1B | $45.0B |
| Short-Term Investments | $13.6B | $14.7B | $14.7B | $16.0B | $6.0B |
| Cash & ST Investments | $74.6B | $74.3B | $65.3B | $70.1B | $51.0B |
| Net Receivables | $20.3B | $19.3B | $23.7B | $21.2B | $22.9B |
| Inventory | $15.0B | $15.6B | $17.2B | $19.0B | $19.2B |
| Other Current Assets | $749M | $812M | $739M | $1.1B | $1.5B |
| Total Current Assets | $110.6B | $109.9B | $107.0B | $111.4B | $94.6B |
| Property, Plant & Equip. | $25.7B | $25.5B | $25.4B | $27.6B | $27.3B |
| Goodwill & Intangibles | $8.2B | $6.7B | $7.5B | $19.3B | $24.4B |
| Long-Term Investments | $18.9B | $20.3B | $5.8B | $0 | $18.8B |
| Other Non-Current Assets | -$1M | -$1M | $23.4B | $28.1B | $8.7B |
| Total Non-Current Assets | $54.6B | $56.4B | $64.6B | $79.0B | $84.7B |
| Total Assets | $165.2B | $166.3B | $171.6B | $190.4B | $179.3B |
| — Liabilities — | |||||
| Accounts Payable | $5.9B | $6.2B | $7.0B | $8.2B | $7.6B |
| Short-Term Debt | $3.9B | $3.9B | $3.9B | $3.9B | $3.9B |
| Deferred Revenue | $7.4B | $9.4B | $0 | $0 | $0 |
| Other Current Liabilities | $5.4B | $7.2B | $7.1B | $4.7B | $8.1B |
| Total Current Liabilities | $19.0B | $20.8B | $19.0B | $30.4B | $20.9B |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Other Non-Current Liab. | $5.6B | $6.9B | $6.9B | $5.9B | $5.4B |
| Total Non-Current Liabilities | $7.8B | $8.7B | $8.8B | $7.4B | $9.9B |
| Total Liabilities | $26.9B | $29.5B | $27.9B | $37.8B | $30.8B |
| — Equity — | |||||
| Common Stock | $23.9B | $23.9B | $23.9B | $23.9B | $24.0B |
| Retained Earnings | $126.3B | $126.1B | $128.5B | $135.2B | $126.4B |
| Accumulated OCI | $0 | $4.9B | $0 | $0 | $10.6B |
| Total Stockholders Equity | $137.7B | $136.3B | $143.8B | $152.6B | $148.5B |
| Total Liabilities & Equity | $165.2B | $166.3B | $171.6B | $190.4B | $179.3B |
| — Key Metrics — | |||||
| Total Debt | $3.9B | $3.9B | $3.9B | $3.9B | $3.9B |
| Net Debt | -$57.2B | -$55.7B | -$46.8B | -$50.2B | -$41.1B |
| Total Investments | $32.5B | $35.0B | $20.5B | $16.0B | $24.9B |